Survey of treatment recommendations for anaplastic oligodendroglioma

被引:84
作者
Abrey, Lauren E.
Louis, David N.
Paleologos, Nina
Lassman, Andrew B.
Raizer, Jeffrey J.
Mason, Warren
Finlay, Jonathan
MacDonald, David R.
DeAngelis, Lisa M.
Cairncross, J. Gregory
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Northwestern Univ, Evanston, IL USA
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[6] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[7] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA
[8] London Reg Canc Ctr, London, ON N6A 4L6, Canada
[9] Univ Calgary, Calgary, AB, Canada
关键词
1p; 19q; anaplastic oligodendroglioma; molecular genetic studies; radiotherapy; survey; temozolomide; treatment recommendations;
D O I
10.1215/15228517-2007-002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Anaplastic oligodendroglioma is a malignant brain tumor uniquely sensitive to treatment with both chemotherapy and radiotherapy. There are few prospective clinical trials for newly diagnosed patients and multiple approaches to the treatment of these patients. This study explored the recommended treatment offered by experts in neuro-oncology. A Web-based survey was developed and distributed to 800 members of the Society of Neuro-Oncology (SNO) who had an e-mail address listed with SNO. Questions addressed use of molecular genetic information and treatment recommendations. A total of 99 clinical SNO members (20%) responded. The majority reported practicing at an academic center in the United States. Two-thirds of respondents see more than five patients with newly diagnosed anaplastic oligodendroglioma annually. Molecular genetic testing was requested for more than 75% of patients, and the results significantly influenced treatment recommendations (p = 0.000003). Regardless of molecular genetic status, the most commonly recommended treatment was the use of concurrent temozolomide and radiotherapy followed by adjuvant temozolomide (18%-34%). The current survey demonstrates that although neuro-oncologists have embraced the use of molecular genetic studies in newly diagnosed anaplastic oligodendroglioma, treatment recommendations vary widely and are often independent of the molecular data.
引用
收藏
页码:314 / 318
页数:5
相关论文
共 18 条
[1]   Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas [J].
Bauman, GS ;
Ino, Y ;
Ueki, K ;
Zlatescu, MC ;
Fisher, BJ ;
Macdonald, DR ;
Stitt, L ;
Louis, DN ;
Cairncross, JG .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (03) :825-830
[2]  
Cairncross G, 2004, J CLIN ONCOL, V22, p107S
[3]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479
[4]   SUCCESSFUL CHEMOTHERAPY FOR RECURRENT MALIGNANT OLIGODENDROGLIOMA [J].
CAIRNCROSS, JG ;
MACDONALD, DR .
ANNALS OF NEUROLOGY, 1988, 23 (04) :360-364
[5]   Oligodendrogliomas: Reproducibility and prognostic value of histologic diagnosis and grading [J].
Giannini, C ;
Scheithauer, BW ;
Weaver, AL ;
Burger, PC ;
Kros, JM ;
Mork, S ;
Graeber, MB ;
Bauserman, S ;
Buckner, JC ;
Burton, J ;
Riepe, R ;
Tazelaar, HD ;
Nascimento, AG ;
Crotty, T ;
Keeney, GL ;
Pernicone, P ;
Altermatt, H .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (03) :248-262
[6]   Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression [J].
Hoang-Xuan, K ;
He, J ;
Huguet, S ;
Mokhtari, K ;
Marie, Y ;
Kujas, M ;
Leuraud, P ;
Capelle, L ;
Delattre, JY ;
Poirier, J ;
Broët, P ;
Sanson, M .
NEUROLOGY, 2001, 57 (07) :1278-1281
[7]  
Ino Y, 2001, CLIN CANCER RES, V7, P839
[8]   Current strategies in treatment of oligodendroglioma: Evolution of molecular signatures of response [J].
Jaeckle, KA ;
Ballman, KV ;
Rao, RD ;
Jenkins, RB ;
Buckner, JC .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (08) :1246-1252
[9]   The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors [J].
McDonald, JM ;
See, SJ ;
Tremont, IW ;
Colman, H ;
Gilbert, MR ;
Groves, M ;
Burger, PC ;
Louis, DN ;
Giannini, C ;
Fuller, G ;
Passe, S ;
Blair, H ;
Jenkins, RB ;
Yang, H ;
Ledoux, A ;
Aaron, J ;
Tipnis, U ;
Zhang, W ;
Hess, K ;
Aldape, K .
CANCER, 2005, 104 (07) :1468-1477
[10]   Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology [J].
Reifenberger, G ;
Louis, DN .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2003, 62 (02) :111-126